Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer

A Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Irinotecan/5-fluorouracil/Isovorin (FOLFIRI) Administered Every 2 Weeks in Patients With Metastatic Colorectal Cancer

The primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (FOLFIRI) in Japanese patients with metastatic colorectal cancer.

Secondary objectives of this study are to assess the safety profile of aflibercept, to determine the pharmacokinetics of aflibercept, to make a preliminary assessment of antitumor effects.

Inclusion Criteria:

• Patients with histologically or cytologically proven malignant tumor of the colon or rectum which is metastatic and inoperable.
• Patients must have received at least one prior line of treatment with any standard of care, who have failed the treatment, or who have not been eligible for standard of care for safety reasons.

Exclusion Criteria:

• Treatment with chemotherapy, hormone therapy, radiotherapy, surgery, blood products, or any investigational agent within 28 days.
• ECOG Performance Status>1
• Anticipated need for a major surgical procedure or radiation therapy during the study.
• Uncontrolled malignant ascites.
• History of brain metastases, spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease on screening CT or MRI scan.
• Pregnant or breast-feeding women.
• Uncontrolled hypertension
• Patients who have previously been treated with aflibercept
• History of abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28 days.
• History of hypersensitivity to any recombinant proteins, irinotecan, fluoropyrimidine or isovorin.
• Known dihydropyrimidine dehydrogenase deficiency.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.